Telix Pharmaceuticals (NASDAQ:TLX) Sets New 52-Week High – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $12.58 and last traded at $12.7070, with a volume of 19242 shares. The stock had previously closed at $11.78.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pixclara (floretyrosine F 18, or 18F-FET), Telix’s amino-acid PET imaging agent for detecting and characterizing gliomas, a form of brain cancer. The approval covers imaging in both adults and children, creating a significant commercial opportunity in the U.S. and advancing Telix’s radiopharmaceutical pipeline. FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: Analysts at Wedbush reaffirmed an Outperform rating and set a $22 price target, signaling substantial potential upside from recent trading levels. The target provides additional investor confidence following the Pixclara approval. Wedbush rating coverage
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, Telix presented an overview of its business and development strategy. The event may improve visibility with institutional healthcare investors, although the supplied transcript does not identify a separate new financial forecast or material corporate announcement. Morgan Stanley Global Healthcare Conference Transcript

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TLX. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, September 2nd. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Monday. Royal Bank Of Canada lowered Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Price Performance

The firm’s 50 day moving average is $11.22 and its two-hundred day moving average is $10.20. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Bank of America Corp DE increased its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the last quarter. XY Capital Ltd bought a new stake in Telix Pharmaceuticals in the 1st quarter valued at $120,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $1,731,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the period. Finally, Lazard Asset Management LLC increased its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.